Rapid screening and early diagnosis of diabetic retinopathy

The prevalence of diabetes is continuously increasing all over the world. The International Diabetes Federation estimated that in 2045 around 700 million people will suffer from diabetes.

Diabetic retinopathy (DR) is one of the most common and serious microvascular complications of diabetes. Screening and early diagnosis of DR are important for the prevention and treatment of this disease. The lack of effective diagnostic biomarkers for DR leads to unsatisfactory curative treatments.

Recently, researchers led by Prof. XU Guowang from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences and their collaborators found that 12-hydroxy arachidonic acid (12-HETE) and 2-piperidone are suitable for the diagnosis of DR, particularly for the early screening of DR. Their study was published in Advanced Science on Oct. 1.

The scientists used mulitplatform metabolomics methods to analyze the serum samples from 905 participants, and to provide comprehensive insights into the abnormal metabolic characteristic and disordered metabolic pathways involved in the onset and development of DR.

Through multivariate/univariate statistical analysis, a novel marker panel consisting of 12-HETE and 2-piperidone was discovered and validated by a two-step strategy. And the panel was able to perform rapid and accurate diagnosis of DR in vitro, showing high diagnostic performance with sensitivity of 80.5—89.4%, specificity of 91.9—93.3%, and area under the receiver operating characteristic curve (AUC) of 0.928—0.946.

Moreover, the marker panel also showed advantages in the early diagnosis of DR, with sensitivity of 81.6—92.9%, specificity of 90.1—93.3%, and AUC of 0.925—0.958.

Source: Read Full Article